Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Race Oncology Ltd. ( (AU:RAC) ).
Racura Oncology announced that CEO Dr. Daniel Tillett has begun early conversion of $1.25 Piggyback Options and acquired shares to ensure funding for its HARNESS-1 lung cancer trial, reaffirming his confidence in the company’s clinical and commercial potential. This action, along with support from other stakeholders, highlights the company’s commitment to advancing its innovative drug pipeline and solidifying its position in the oncology market.
More about Race Oncology Ltd.
Racura Oncology (ASX: RAC) is a clinical-stage biopharmaceutical company focused on cancer treatment. Its leading asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent targeting cancer growth regulators like MYC. The company is pursuing advanced clinical trials for leukemia and lung cancer and exploring partnerships to expand access to its therapies.
Average Trading Volume: 504,986
Technical Sentiment Signal: Buy
Current Market Cap: A$465.6M
Learn more about RAC stock on TipRanks’ Stock Analysis page.